Table 2.

Univariate analysis of baseline characteristics associated with time-to-progression events.

		Events/Patients	HR (95% CI. p-Value)
Age	Per year increase	78/349	1.02 (1.00–1.04, p = 0.010)
Deauville Score	DV1-3	51/306	1.00 (ref)
	DV4-5	27/43	6.74 (4.21–10.79, p < 0.001)
International Prognostic Index	High ≥ 3	44/130	1.00 (ref)
	Low < 3	34/212	0.41 (0.26–0.64, p < 0.001)
	Unavailable	0/7	0.00 (0.00–Inf, p = 0.995)
Overall Bulky Status	bulky	13/48	1.00 (ref)
	not bulky	59/268	0.72 (0.39–1.31, p = 0.280)
	Unavailable	6/33	0.60 (0.23–1.58, p = 0.303)
ECOG Score	High ≥ 2	8/14	1.00 (ref)
	Low < 2	68/328	0.26 (0.13–0.55, p < 0.001)
	Unavailable	2/7	0.33 (0.07–1.59, p = 0.168)
Extranodal Involvement	No	26/132	1.00 (ref)
	Yes	52/216	1.41 (0.88–2.25, p = 0.157)
	Unavailable	0/1	0.00 (0.00–Inf, p = 0.996)
Presence of B Symptoms	No	32/185	1.00 (ref)
	Yes	33/105	2.10 (1.29–3.41, p = 0.003)
	Unavailable	13/59	1.32 (0.69–2.51, p = 0.404)
Receipt of Consolidative RT	RT-omitted	65/269	1.00 (ref)
	RT-treated	13/80	0.81 (0.45–1.48, p = 0.501)
Elevated LDH	No	12/83	1.00 (ref)
	Yes	65/260	1.89 (1.02–3.50, p = 0.043)
	Unavailable	1/6	1.23 (0.16–9.46, p = 0.843)
Hemoglobin Levels	Mean (SD)	78/348	0.84 (0.75–0.93, p = 0.001)
Marrow Involvement	No	64/320	1.00 (ref)
	Yes	13/24	2.76 (1.52–5.01, p = 0.001)
	Unavailable	1/5	2.06 (0.29–14.93, p = 0.473)
Ann Arbor Staging	Ann Stage I/IE	3/65	1.00 (ref)
	Ann Stage II/IIE	14/99	3.50 (1.01–12.18, p = 0.049)
	Ann Stage III/IIIE	22/52	13.06 (3.91–43.67, p < 0.001)
	Ann Stage IV	39/132	8.31 (2.57–26.89, p < 0.001)
	Unavailable	0/1	0.00 (0.00–Inf, p = 0.997)
Ann Arbor Staging	Ann Stage I/II	17/164	1.00 (ref)
	Ann Stage III/IV	61/184	3.94 (2.30–6.74, p < 0.001)
	Unavailable	0/1	0.00 (0.00–Inf, p = 0.997)